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Background: Typhoid fever is a systemic illness which in high-income countries mainly affects travellers. The
incidence is particularly high on the Indian subcontinent. Travellers who visit friends and relatives (VFR) have been
shown to have a different risk profile than others. We wished to identify main characteristics for travellers infected
with S. Typhi considering both clinical and laboratory findings in order to provide for faster and better diagnostics
in the future. The outcome of treatment, especially concerning relapse, was evaluated as well.
Methods: Retrospectively collected data from 19 adult cases of typhoid fever over a 5-year period at the
Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre Denmark.
Results: The patients were young adults, presenting with symptoms within a month after travelling. 84% were
returned from travelling in the Indian subcontinent. 17 out of 19 patients were VFR-travellers. The main symptoms
were fever (100%), gastrointestinal symptoms (84%), headache (58%) and dry cough (26%). Laboratory findings
showed elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH) in all cases and elevated alanine
transaminase (ALAT) in 47% of cases. In primary cases 4 isolates were fully susceptible to ciprofloxacin, the
remaining were intermediate susceptible. Relapse occurred in 37% of the cases and only in cases where the patient
was infected by a strain with intermediate susceptibility.
Conclusions: Better pre-travel counselling should be given to VFR-travellers. The main symptoms and laboratory
findings confirm previous findings. The relapse rate was unexpected high and could be correlated to ciprofloxacin-
resistance.
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Typhoid fever is a systemic infectious disease caused by
Salmonella enterica ssp. enterica serovar Typhi. (S. Typhi).
World Health Organization estimates that S. Typhi world-
wide causes 22 million (16 mill. - 33 mill.) illnesses and
200.000 deaths annually [1]. In endemic areas typhoid
fever is an illness primarily affecting children and young
adults whereas in high-income countries it is mainly a dis-
ease of returning travellers [2-4]. In Denmark, most
reported cases today can be related to travelling. In 2008–
2010 17–21 cases were reported each year [5]. In the
period 1986–1990 the average was 21 [2].
The disease only affects humans and is transmitted
through contaminated food or water. Therefore, infection* Correspondence: frejacb@gmail.com
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reproduction in any medium, provided the oris closely related to poor sanitary conditions. Endemic
areas include South-East Asia, South America, Africa and
certain areas in the former USSR [1]. The incidence is par-
ticular high in the Indian subcontinent and has been
shown to be 10–29 times higher in India and Pakistan
compared to China and Vietnam [6].
The clinical findings are usually uncharacteristic, but
traditional findings include fever, relative bradycardia,
splenomegaly and rose spots [4]. If left untreated the
mortality is between 10-40% compared to 1-4% with
treatment [1]. In Denmark mortality is less than 1% [7].
The diagnosis is usually confirmed by cultivating the
bacteria from blood or faeces. Blood culture is consid-
ered golden standard even though the sensitivity is as
low as 80% [8].
When observing travellers it is important to differenti-
ate between travelling tourists and emigrants visitingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Basic characterization of patients and acquisition
of infection
Number of patients
Total number 19 (100%)
Women 11 (58%)
Age, median 26 (range 15–40)
VFR- traveller 17 (89%)
Days spent abroad, median 30 (range 14–150)
Days since return to Denmark, median 16 range (0–26)
Days since onset of symptoms, median 6.5 (range 0–26)
Vaccinated against typhoid fever 0 (0%)
Acquisition in Pakistan 14 (74%)
Acquisition in Asia outside Pakistan 3 (16%)
Acquisition in Middle East 1 (5%)
Acquisition in Sub-Saharan Africa 1 (5%)







Abdominal pain 6 (32)
Dry cough 5 (26)
Joint or muscle pain 4 (21)
Shivering 4 (21)
Constipation 3 (16)
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ous studies have shown a different risk profile in this
group [2,9-12]. One study found more patients with S.
Typhi bacteraemia among holiday-travellers than VFR
[13], but most studies agree that VFR-travellers carry a
greater risk than tourists [9,10]. In one Danish study ob-
serving the period 1986–90 more than 50% of the af-
fected individuals belonged to the VFR group [2].
In order to provide better diagnostics and treatment
in the future, we studied the clinical presentation, the
travel history, the laboratory findings, and the response
to treatment for patients with S. Typhi bacteraemia, and
especially relapse in relation to resistance.
Methods
We included retrospectively adult cases of typhoid fever
from February 2006 till February 2010 treated at the De-
partment of Infectious Diseases, Copenhagen University
Hospital, Hvidovre, Hospital, Denmark. The inclusion
criterion was the presence of at least one positive blood
culture with S. Typhi, which was identified through the
database in the Department of Clinical Microbiology,
Hvidovre Hospital.
Clinical and laboratory findings were retrieved from
patient’s records and the various hospital databases. Per-
mission was granted from the Danish Data Protection
Agency. Ethical approval was not required for this study
according to Danish Law.
All patients were examined with blood-culture drawn
shortly after admittance, as a minimum of four flasks, (two
aerobic and two anaerobic flasks, BactAlert®, BioMerieux,
France), and often additional blood-cultures were per-
formed depending on the clinical presentation of the
patients. Stool samples were examined for enteric patho-
gen bacteria in most patients.
Fever was defined as a temperature >37.5°C.
Relapse was defined as isolation of S. Typhi in new
blood cultures drawn after the patient had completed
the antimicrobial treatment.
To handle the data OpenOffice Calculator version 3.1.1
was used. Numerical data are presented as the mean and
range.
Results
Demographics and travel history
19 patients were diagnosed with typhoid fever at the De-
partment of Infectious Diseases, Hvidovre University
Hospital during the study period. All were young adults
with a median age of 26 years (range 15–40) (Table 1).
The patients had been travelling with a median of
30 days (range 14–150 days). All patients developed symp-
toms within a month (median 16 days, range 0–26 days)
after returning to Denmark and were referred to the De-
partment of Infectious Diseases, Hvidovre Hospital.The time between onsets of symptoms until patients
sought medical attention were median 6.5 days (range
2–26 days). None of the patients received vaccination
for typhoid fever prior to travelling abroad (Table 1).
All were infected during travelling outside Denmark,
the majority in the Indian subcontinent (84%), primarily
Pakistan (Table 1). In 17 of the 19 cases, the patients
were emigrant VFR-travellers. All of these were infected
in the Indian subcontinent.
Symptoms and laboratory findings
The main complaint was fever. All of the patients had at
some point experienced fever, although only 13 (68%)
presented fever at admittance. 16 (84%) patients had at
least one gastrointestinal symptom (diarrhoea, nausea,
abdominal pain and/or constipation), of these 13 had
diarrhoea (68%). Eleven patients had headache (58%),
and 5 (26%) experienced dry cough (Table 2). There were
no reported cases of rose spots or relative bradycardia.
As given in Table 3 the values of CRP and LDH were
elevated at admittance in all patients examined. ALAT
Table 3 Laboratory results of adults patients with
typhoid fever




Haemoglobin (7.0–11.0 mmol/L) 7.9 (6.1–10.0)
MCHC1 (19.0–22.0 mmol/L) 21.5 (20.0–22.6)
Serum Sodiium (136–146 mmol/L) 135 (129–140)
Serum Potassium (3.5–5.0 mmol/L) 3.8 (3.4–4.8)
Total white blood cell count (3.0–9.0 10E9/L) 6.1 (2.7–14.2)
Neutrophil count (1.8–7.4 10E9/L) 4.1 (1.6–11.8)
Platelet count (150–400 10E9/L) 176 (112–292)
ALAT2 (Male 10–70 U/L; Female 10–45 U/L) 50 (20–121)
LDH3 (105–205 U/L) 367 (223–976)
Creatinine (Male 60–130 μmol/L; Female
40–110 μmol/L)
75 (61–107)
CRP4 (<10 mg/L) 73.5 (20–199)
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counts were low within the normal range in 13 cases
and below in 6. Haemoglobin values were below reference
value in 3 cases, the remaining were normal. The total
white blood cells counts were normal in 16 patients, but
one had low and two had elevated values. Neutrophil
counts were normal in 15 cases, low in one and elevated
in three cases. Serum sodium was slightly decreased in 12
cases as were Serum potassium in two cases.
All patients were examined and found negative for
malaria infections. Faeces examination at admittance
was performed in 13 of the primary cases, and in 3 of
the 6 cases of relapses. S. Typhi was cultured from faeces
in 5 primary cases, and in one secondary case.
All strains were examined for susceptibility to
ampicillin, ceftriaxone, sulfonamid-trimethoprim, piv-
mecillinam, and ciprofloxacin. None of the isolates were
tested for azithromycin and none isolates were multi
drug resistant, as defined as resistance to ampicillin,
chloramphenicol and sulfonomid-trimethoprim. Cip-
rofloxacin susceptibility testing was performed in all
primary and secondary isolates, using E-tests, and
MIC ≤ 0.06 μg/mL were fully susceptible, MIC 0.125 –
1 μg/mL were intermediate susceptible, and > 1 μg/mL
were regarded resistant. In primary cases, 4 isolates
were fully susceptible, and the rest were intermediate
susceptible to ciprofloxacin. In all cases of relapse a
similar isolate were found regarding the antibiogram,
except for one case, where both the primary ciprofloxa-
cin intermediate resistant isolate was found together
with a fully susceptible isolate.Treatment and outcome
All patients were hospitalized for a median of six days
(1–14 days). Empiric antimicrobial treatment was started
in 10 cases. 6 patients were treated exclusively with cef-
triaxone and 1 with both ceftriaxone and ciprofloxacin.
2 were initially treated with ciprofloxacin and 1 with piv-
mecillinam. Once microbiological diagnosis was confirmed
all but one were switched to ceftriaxone treatment. The
median time of treatment was 14 days (range 10–28 days)
for all cases. The median time of treatment with ceftriax-
one was 10 days (range 3–14 days). Overall, 11 patients
received oral treatment in the last part of the treatment
course. Ciprofloxacin was administered in five cases; in
one of these the bacteria was fully susceptible to ciproflox-
acin and in the rest the isolates had reduced susceptibility.
The remaining cases were treated with piv-mecillinam,
pondocillin or sulphamethoxazol-trimethoprim.
Relapse was confirmed in 7 (37%) cases with a median
of 20.5 days (range 13–27 days) between the last day of
treatment and the day patients returned with a relapse.
Patients were hospitalized with relapse for a median of
12 days (range 3–17 days). All patients with relapse were
initially infected by a strain not fully susceptible to cip-
rofloxacin. All had been treated with ceftriaxone for a
median of 10 days (range 4–14 days), 3 exclusively with
ceftriaxone (10–14 days), 2 with ceftriaxone and cipro-
floxacin, 1 with ceftriaxone and pondocillin and 1 with
ceftriaxone, ciprofloxacin and piv-mecillinam.
Six cases were retreated with ceftriaxone between 10
and 14 days. Of these, 5 received additional treatment
with amoxicillin, sulphametoxazol-trimethoprim or piv-
mecillinam. One patient was retreated with a combin-
ation of piv-mecillinam, ciprofloxacin, and gentamicin.
In total, the relapse was treated for a median of 40 days
(range 10–42 days). One patient was diagnosed with
gallstones and had an elective cholecystectomia. There
was no second relapse and no fatal outcome.
12 cases were successfully treated and did not present
with relapse. All but one received ceftriaxone and were
treated with this for a median of 7 days (range 3–14 days)
this being shorter than the cases in which relapse oc-
curred. 8 out of 12 patients were infected with a strain
with reduced sensitivity to ciprofloxacin.
Discussion
Patients presenting with typhoid fever in high-income
countries are usually young adults of 40 years of age or
younger, which could simply reflect the age of travellers
to endemic areas [3,10]. The VFR-group seems to be
more vulnerable to typhoid fever than common tourists,
as 89% of our population were VFR. None of the cases
were infected in Denmark. Consistent with results of
previous studies 84% of the cases in this study were
infected while visiting the Indian subcontinent [9,10].
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in this region [2]. Travelling to these destinations ap-
pears to be associated with increased risk of infection
[2,4,12,14]. While the general risk of developing typhoid
fever after travelling to a low-income country is esti-
mated to be 1:100.000, the risk is as high as 30:100.000
on the Indian subcontinent [9]. In one British study, in-
cluding both typhoid and paratyphoid fever, it was found
that 84% were likely to have been infected in India and
only 5.9% in Pakistan [11]. The majority were, as in this
study and other studies, VFR-travellers [2,9,12,14]. The
large number of patients being infected in India compared
to present study could be explained by the relative larger
population of people of Indian origin than of Pakistan ori-
gin in Great Britain compared to Denmark [15,16].
Differences in travel patterns might explain the in-
creased number of infected among the VFR-travellers: It
seems reasonable to assume that this group has less con-
trol over their diet and spend more time in rural areas
living in close contact with the locals than other travel-
lers. This would give them a risk profile similar to the
locals [11]. It also makes them at greater risk of contrac-
tion other travel-related illnesses such as hepatitis A
[17]. Therefore, family doctors should pay great atten-
tion to pre-travel advise directed at VFR-travellers re-
garding hygiene precautions and vaccine possibilities.
Even though vaccines on the market today only seem
to prevent 70% of the cases [1], vaccination could be
relevant for this specific group. In Australia, two studies
of febrile travellers returning from abroad showed that
typhoid fever was 10–11 times more likely in non-
vaccinated individuals compared to those who received
vaccination prior to travelling [18,19].
The patients in this study, in line with previous
studies, sought medical attention within a month after
returning from travelling [3,10].
68% of the patients were febrile at time of admittance;
the rest reported to have experienced fever at some
point in their illness. The reason why fever could not be
documented in all cases could be explained by in-
accuracy in the measurement as well as temperature
fluctuation. The patients could also have been taking
paracetamol prior to seeking medical attention without
this being brought to the clinician’s attention. Despite
this, the finding highlights that fever is the most com-
mon finding in patients affected with typhoid fever [12].
The clinical findings in this study were overall com-
parable to former studies where fever, headache and
diarrhoea occurred with an incidence of 100%, 62-68%
and 50-59%, respectively [3,10]. Typhoid fever should
therefore be considered in all patients with a fever and a
relevant travel history.
Even though gastroenteritis is not a key symptom, 84%
of our cases presented with a gastrointestinal symptomin one form or another and such a finding should sup-
port the diagnosis.
Clinical findings traditionally associated with typhoid
fever include rose spots, splenomegaly and relative brady-
cardia [4]. None of the patients in this study presented
with rose spots and there were no reports on splenomeg-
aly or relative bradycardia.
Splenomegaly and rose spots would most likely be
found at the clinical examination when the patient was ad-
mitted. Relative bradycardia could be a symptom missed
by the clinician.
In three studies including larger populations (100, 92
and 42 cases respectively) only 4.5-15% presented with
splenomegaly, 4-9% with rose spots [3,10,12] and 13-27%
with relative bradycardia. This indicates that these symp-
toms are not common in travellers and should only play a
minor role in the diagnostics in high-income countries.
The most significant finding in the blood samples was
the elevated LDH and CRP levels in all cases. This how-
ever cannot be used alone since LDH and CRP has been
found elevated in blood samples from all febrile travellers
in a previous study [13], as well as in malaria cases [20].
Because of this, these two parameters are not that useful
to the clinician, since malaria is the most important differ-
ential diagnosis. In other studies ALAT has been found to
be elevated with median levels from 56–75 U/L [10,13] or
raised above normal in 82% of the cases [12]. In this study
ALAT was elevated in 47% of the cases with a median
level of 50 U/L when including both males and females.
Elevated ALAT at time of admittance should support
the diagnosis. Serum sodium in the low end of normal
range was found in comparable studies [3,10,12] as well
as in this study.
All patients but one in this study received empirical
treatment with ceftriaxone though it was not consistent
for how long the treatment was maintained. Multi drug
resistant (MDR) and ciprofloxacin resistant strains of S.
Typhi is a common problem especially for travellers
returning from the Indian subcontinent. Therefore cip-
rofloxacin should not be the drug of choice for empirical
treatment [4]. It may only be considered for empirical
treatment if the patient is contaminated outside the
Indian subcontinent where the amount of resistant
strains is still not critically high.
An alternative drug is azithromycin. It can be adminis-
trated orally and is therefore more convenient for the
patient, especially in the last part of the treatment when
hospitalization is no longer needed. Drug susceptibility
test for azithromycin was not routinely performed on
patient samples and might be worth considering in the
future, since a cochrane-review from 2008 indicates that
azithromycin could cause fewer cases with relapse than
ceftriaxone [21]. This study however still needs to be
performed on travellers [4].
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with enteric fever experienced relapse [4]. In a French
study from 2001, relapse rate was 3% [3]. In the present
study the relapse rate was 37%, which is an unexpected
high rate.
It was not possible to determine a connection between
the duration of treatment and the risk of relapse, and so,
optimal length of treatment needs further investigation.
However, it is noticeable that none of the patients with
relapse were infected by ciprofloxacin susceptible strains.
In the French study only two patients were infected with
strains resistant to ciprofloxacin [3]. This indicates that
ciprofloxacin-resistant strains are more difficult to clear
even with antibiotics that they are found to be sensitive
for. Similar results have been found in another study [9],
suggesting a connection between the high level of re-
lapse and the rising resistance to ciprofloxacin. No con-
nection was found between the risk of relapse and the
onset of treatment with ceftriaxone [10].
Limitations to the present study include the low num-
ber of cases, as well as the fact that this study was done
retrospectively and that the material does not allow for
statistical testing of results. This however would not in-
fluence the data on relapse and para clinical findings.
Despite of limitations, this study provides a guide to
which patients and symptoms might indicate typhoid
fever. It is also consistent with previous national and
international findings.Conclusions
Typhoid fever should be considered in young febrile adults
returning from a VFR-trip to the Indian subcontinent, in a
Danish setting, mainly Pakistan. Headache, gastrointestinal
symptoms and elevated levels of LDH and CRP support
the diagnosis.
Relapse was more frequent than expected and is asso-
ciated with ciprofloxacin resistance. The doctor should
be aware of this and take this into consideration when
informing the patients. It is possible that azitromycin
could reduce the rate of relapse, and this should be in-
vestigated further.
Finally, this study highlights the need for better pre-
travel counselling of VFR-travellers.
Competing interests
The authors have no conflicts of interest to declare and no involvement in
any company with direct or indirect financial interest in the subject of the
manuscript. No funding was received.
Authors’ contributions
FCB collected data, analysed them and drafted the manuscript. JDK initiated
the idea of looking into this specific group of patients, collected
microbiological data and wrote parts of the manuscript concerning
laboratory methods and revised the manuscript as a whole. ISJ drafted the
design of the study, wrote parts of the manuscript, and revised it. All authors
read and approved the final manuscript.Author details
1Department of Infectious Diseases, Copenhagen University Hospital,
Hvidovre Hospital, Hvidovre, Denmark. 2Department of Clinical Microbiology,
Copenhagen University Hospital, Hvidovre Hospital, Hvidovre, Denmark.
3Department of Infectious Diseases, Odense University Hospital, Odense,
Denmark.
Received: 23 July 2013 Accepted: 5 August 2013
Published: 11 August 2013
References
1. World Health Organization: Initiative for Vaccine Research. http://www.who.
int/vaccine_research/diseases/diarrhoeal/en/index7.html.
2. Lester A, Mygind O, Jensen KT, Jarløv JO, Schønheyder HC: Tyfus og
paratyfus i Danmark 1986–1990: Epidemiologiske aspekter samt omfang
af bakteriologisk opfølgning af patienter. Ugeskr Laeger 1994,
156(25):3770–3775.
3. Caumes E, Ehya N, Nguyen J, Bricaire F: Typhoid and paratyphoid fever: a
10-year retrospective study and 41 cases in a Parisian hospital. J Travel
Med 2001, 8:293–297.
4. Basnyat B, Maskey AP, Zimmerman MD, Murdoch DR: Enteric (typhoid)
fever in travelers. Clin Infect Dis 2005, 41:1467–72.
5. EPI-nyt uge 11 2011. http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2011/
Uge%2011%20-%202011.aspx.
6. Meltzer E, Schwartz E: Enteric fever: a travel oriented view. Curr Opin Infect
Dis 2010, 23(5):432.
7. Tyfus. http://www.ssi.dk/Service/Sygdomsleksikon/T/Tyfus.aspx.
8. Baker S, Favorov M, Dougan G: Searching for the elusive typhoid
diagnostic. BMC Infect Dis 2010, 10:45.
9. Connor BA, Schwartz E: Typhoid and paratyphoid fever in travellers.
Lancet Infect Dis 2005, 5(10):623–8.
10. Clark TW, Daneshvar C, Pareek M, Perera N, Stephenson I: Enteric fever in a
UK regional infectious diseases unit: A 10 year retrospective review.
J Infect 2010, 60:91–98.
11. Angell SY, Cetron MS: Health disparities among travelers visiting friends
and family abroad. Ann Intern Med 2005, 142(1):67–72.
12. Patel TA, Amstrong M, Morris-Jones SD, Wright SG, Doherty T: Imported
enteric fever: case series from the hospital for tropical diseases, London,
United Kingdom. Am J Trop Med Hyg 2010, 82(6):1121–1126.
13. Bottieau E, Clerinx J, Van den Enden E, Van Esbroeck M, Colebunders R, Van
Gompel A, et al: Fever after a stay in the tropics; diagnostic predictors of
the leading tropical conditions. Medicine (Baltimore) 2007, 86(1):18–25.
14. Brunvatne R, Blystad H, Hoel T: Innvandrere og helsefarer ved reise til
opprinnelig hjemland. Tidsskr Nor Laegeforen 2002, 122(16):1568–72.
15. Danmarks Statistik -Statistikbanken.dk. http://www.statistikbanken.dk/
statbank5a/default.asp?w=1366.
16. Migration Statistics Annual Report; 2008. http://www.ons.gov.uk/ons/rel/
migration1/migration-statistics/2008/index.html.
17. Luxemburger C, Dutta AK: Overlapping epidemiologies of hepatitis A and
typhoid fever: the needs of the traveler. J Travel Med 2005,
12(Suppl 1):s12–21.
18. O’Brien D, Tobin S, Brown GV, Toressi J: Fever in returned travelers: review
of hospital admissions for a 3-year period. Clin Infect Dis 2001, 33(5):603–9.
19. O’Brien DP, Leder K, Matchett E, Brown GV, Torresi J: Illness in returned
travelers and immigrants/refugees: the 6-year experience of two
Australian infectious diseases units. J Travel Med 2006, 13(3):145–152.
20. Gjørup IE, Vestergaard LS, Møller K, Rønn AM, Bygbjerg IC: Laboratory
indicators of the diagnosis and course of imported malaria. Scand J Inf
Dis 2007, 39:707–713.
21. Effa EE, Bukirwa H: Azithromycin for treating uncomplicated typhoid and
paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008,
4, CD006083.
doi:10.1186/1756-0500-6-315
Cite this article as: Barrett et al.: Cases of typhoid fever in Copenhagen
region: a retrospective study of presentation and relapse. BMC Research
Notes 2013 6:315.
